OncoVar: an integrated database and analysis platform for oncogenic driver variants in cancers
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The prevalence of neutral mutations in cancer cell population impedes the distinguishing of cancer-causing driver mutations from passenger mutations. To systematically prioritize the oncogenic ability of somatic mutations and cancer genes, we constructed a useful platform, OncoVar (https://oncovar.org/), which employed published bioinformatics algorithms and incorporated known driver events to identify driver mutations and driver genes. We identified 20 162 cancer driver mutations, 814 driver genes and 2360 pathogenic pathways with high-confidence by reanalyzing 10 769 exomes from 33 cancer types in The Cancer Genome Atlas (TCGA) and 1942 genomes from 18 cancer types in International Cancer Genome Consortium (ICGC). OncoVar provides four points of view, ‘Mutation’, ‘Gene’, ‘Pathway’ and ‘Cancer’, to help researchers to visualize the relationships between cancers and driver variants. Importantly, identification of actionable driver alterations provides promising druggable targets and repurposing opportunities of combinational therapies. OncoVar provides a user-friendly interface for browsing, searching and downloading somatic driver mutations, driver genes and pathogenic pathways in various cancer types. This platform will facilitate the identification of cancer drivers across individual cancer cohorts and helps to rank mutations or genes for better decision-making among clinical oncologists, cancer researchers and the broad scientific community interested in cancer precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434 · cited 2×
“org) have been widely used as a resource for allele frequency estimates in the context of rare disease, which can improve power for disease gene discovery and exploring the biological impact of genetic variation (41,42).”
MethodKumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521 · cited 12×
“Cumulated proportion of patients of all the thirty driver genes identified by OncoVar and annotated as the candidate actionable genes by OncoKB for each cancer type.”
ResultInfluentialCOSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes
Siepel, A., Bejerano, G., Pedersen, J. S., Hinrichs, A. S., Hou, M., Rosenbloom, K., Clawson, H., Spieth, J., Hillier, L. W., Richards, S., et al. (2005) · Genome Research · doi:10.1101/gr.3715005 · Cited by 3,971 · cited 1×
“Similar to our previous study (31), we obtained predictive scores and the pathogenicity consequences of missense variants from 23 in silico algorithms or tools, including SIFT (50), PolyPhen2-HDIV (51), PolyPhen2-HVAR (51), LRT (52), MutationTaster (53), MutationAssessor (54), FATHMM (55), PROVEAN (56), MetaSVM (57),…”
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
Self-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants
Ioannidis, N. M., Rothstein, J. H., Pejaver, V., Middha, S., McDonnell, S. K., Baheti, S., Musolf, A., Li, Q., Holzinger, E., Karyadi, D., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.08.016 · Cited by 2,908
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546
Self-citationComprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256 · cited 5×
“OncoVar identified many known driver genes which are consistent with results by other methods including CGC (49), CTAT (31), OncoKB (50), IntOGen (37) and several novel driver genes.”
BackgroundMethodResultInfluentialSelf-citationCOSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922 · cited 1×
“Moreover, OncoVar identified 23 and 7 novel driver genes from TCGA and ICGC pan-cancer cohorts, respectively, compared with four well-known databases including CGC (80), OncoKB (33), IntOGen (37) and CTAT (30) (Figure 4B, C).”
ResultIdentifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++
Davydov, E. V., Goode, D. L., Sirota, M., Cooper, G. M., Sidow, A., & Batzoglou, S. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001025 · Cited by 1,757
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2019) · doi:10.1101/531210 · Cited by 1,662
Somatic mutation in cancer and normal cells
Martincorena, I., & Campbell, P. J. (2015) · Science · doi:10.1126/science.aab4082 · Cited by 1,396 · cited 1×
“Early somatic mutations in coding regions can cause developmental disorders (2), whereas progressive accumulation of somatic mutations throughout life can lead to cancer (3).”
BackgroundIdentifying novel constrained elements by exploiting biased substitution patterns
Garber, M., Guttman, M., Clamp, M., Zody, M. C., Friedman, N., & Xie, X. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp190 · Cited by 370 · cited 1×
“Similar to our previous study (31), we obtained predictive scores and the pathogenicity consequences of missense variants from 23 in silico algorithms or tools, including SIFT (50), PolyPhen2-HDIV (51), PolyPhen2-HVAR (51), LRT (52), MutationTaster (53), MutationAssessor (54), FATHMM (55), PROVEAN (56), MetaSVM (57),…”
Kosmicki, J. A., Samocha, K. E., Howrigan, D. P., Sanders, S. J., Slowikowski, K., Lek, M., Karczewski, K. J., Cutler, D. J., Devlin, B., Roeder, K., et al. (2017) · Nature Genetics · doi:10.1038/ng.3789 · Cited by 340 · cited 1×
“org) have been widely used as a resource for allele frequency estimates in the context of rare disease, which can improve power for disease gene discovery and exploring the biological impact of genetic variation (41,42).”
MethodRubio-Perez, C., Tamborero, D., Schroeder, M. P., Antolín, A. A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., & Lopez-Bigas, N. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.007 · Cited by 296 · cited 1×
“The landscape of targeted therapies The development of therapies targeting altered driver proteins provides the promise of precision cancer medicine (83).”
BackgroundIn silico tools for splicing defect prediction: a survey from the viewpoint of end users
Jian, X., Boerwinkle, E., & Liu, X. (2014) · Genetics in Medicine · doi:10.1038/gim.2013.176 · Cited by 146
Cited by
Computed cancer interactome explains the effects of somatic mutations in cancers
Zhang, J., Pei, J., Durham, J., Bos, T., & Cong, Q. (2022) · Protein Science · doi:10.1002/pro.4479 · Cited by 31
“We obtained SMMs in 12,711 cancer patients from the OncoVar database.(36) We assigned these SMMs to 17,515 reviewed human entries in UniProt that can be unambiguously mapped to the reference genome GRCh38, and the average SMM rate for these proteins is 0.”
MethodSen, N., Anishchenko, I., Bordin, N., Sillitoe, I., Velankar, S., Baker, D., & Orengo, C. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac187 · Cited by 25
Cancer-driving mutations are enriched in genic regions intolerant to germline variation
Vitsios, D., Dhindsa, R. S., Matelska, D., Mitchell, J., Zou, X., Armenia, J., Hu, F., Wang, Q., Sidders, B., Harper, A. R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo6371 · Cited by 14
An interpretable molecular framework for predicting cancer driver missense mutations
Yang, Y., Sun, W., Liu, Y., Zhang, J., & Li, M. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2524289123 · Cited by 3
“The CDG set was integrated from IntOGen (45), OncoVar (46), NCG (47), Cancer Gene Census (48), and ClinGen (49), yielding 1,050 unique genes.”
A multimodal framework for comprehensive driver variant prediction in cancer
Yang, H., Chen, Y., Zhou, T., Wang, Y., Zhou, Q., Xiao, T., Zhang, Q., Zhang, J., Li, D., & Wang, Z. (2025) · Communications Medicine · doi:10.1038/s43856-025-01209-7 · Cited by 2
Metadata
- Authors
- Wang, T., Ruan, S., Zhao, X., Shi, X., Teng, H., Zhong, J., You, M., Xia, K., Sun, Z., & Mao, F.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-12
- Volume
- 49
- Issue
- D1
- Pages
- D1289-D1301
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W3098804002
- Cited by
- 98
- References
- 18
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.